TD Cowen raises target to USD 3.50 for Quanterix stock
Published on 10/16/2026 at 04:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and China approvals
- TD Cowen raised its target to USD 3.50 on October 13, 2026.
- China approvals covered four Quanterix biomarker tests on October 7, 2026.
- Quanterix had a USD 145.2 million market value and a USD 2.15 to USD 8.77 52-week range on October 15, 2026.
Quanterix Corporation (ISIN US74766Q1013) became the subject of a higher analyst target when TD Cowen lifted its target to USD 3.50 from USD 3.00 on October 13, 2026, while keeping a Hold rating, according to Markets Insider. The move followed a Q3 earnings preview and puts the target above the latest dated Nasdaq price.
Three dated developments shape the stock
Quanterix released second-quarter 2026 results on August 10, 2026, with revenue of USD 32.91 million and net loss of USD 48.93 million. The investor-relations page identifies the release and the reporting period, while the standardized quarterly figures show the reported amounts at June 30, 2026.
On October 7, 2026, Quanterix and Innovita announced regulatory approvals in China for the HD-X and SR-X instruments and testing kits covering four neurology biomarkers. The announcement included p-Tau 217, GFAP, p-Tau 181 and NfL, according to Yahoo Finance.
What does the target change mean?
The target increase of USD 0.50 equals 16.67 percent and gives the analyst view a concrete benchmark against the latest dated market value. The Hold rating, however, keeps the assessment balanced rather than turning the note into a bullish call.
Market value and reporting context
Quanterix had a market capitalization of USD 145.2 million on October 15, 2026. Its 52-week range was USD 2.15 to USD 8.77 on the same date, placing the company in a high-volatility small-cap segment of the life science tools market.
The latest available Nasdaq quotation stood at USD 3.07 on October 15, 2026 at 4:00 p.m. ET. That level was USD 0.43 below the TD Cowen target, a gap of 12.29 percent relative to the target.
Next dated event
Quanterix's investor-relations calendar lists its second-quarter earnings call on August 10, 2026, while the October 13, 2026 analyst action is the latest dated event in the reviewed period. The China approvals provide an operating angle because they extend the SIMOA platform into four approved biomarker applications.
Small-cap valuation stays event driven
The USD 145.2 million market value and USD 2.15 to USD 8.77 annual range show why target revisions and regulatory milestones can materially shape the trading narrative.
Market context: Market report S&P 500.
